Biopharmaceuticals

MarketReports.com | Pharmaceuticals & Healthcare | Biotechnology |  Biopharmaceuticals

2012 Biomet Company Profile & Analysis: Biologics Division Price Single License Hard-Copy $2,995.00 Single License PDF $2,995.00 Corporate License PDF $3,995.00 Publication Date: October 2011 Pages: 64 Publisher: iData Research Table of Contents Biomet is one of the five largest orthopedic implant manufacturers in the world, with distribution in the U.S., Europe, Asia and a number of emerging markets. The company has also expanded into areas such as sports medicine and dental medical devices. Biomet's key joint reconstruction business unit accounted for the bulk of the company's revenues in the calendar year of 2011. Sports medicine and small joint reconstructive surgery were two of the fastest-growing areas for Biomet, both of which continued multi-year trends. However Biomet’s market share and areas of potential growth varied significantly by geographical region. This report includes: • Company overview • Financial Metrics • Product Pipeline • SWOT Analysis • Market Shares by Country The business units covered in this report include: • Bone Graft Substitutes - Allograft / DBM - Synthetic Bone Void Fillers • Cell Concentration • Hyaluronic Acid Viscosupplementation

Generic Growth Strategies - Manufacturers to Increase Focus on Super Generics and Biosimilars to Drive Revenues Price Single User $3,500.00 Site License $7,000.00 Global Site License $10,500.00 Publication Date: 09-May-2011 Format: PDF Pages: 69 Publisher: GBI Research More...

Paradigm Shift in R&D from Small Molecules to Biologics and Need for More Efficient Logistics Infrastructure Price Single User $500.00 Site License $1,000.00 Global Site License $1,500.00 Publication Date: 05-Apr-2011 Format: PDF Pages: 9 Publisher: GlobalData More...

Upstream Processing in Biopharmaceuticals - Increasing use of Low-Cost Disposable Bioreactors to Drive the Upstream Bioprocessing Market Price Single User $3,500.00 Site License $7,000.00 Global Site License $10,500.00 Publication Date: 25-Mar-2011 Format: PDF Pages: 109 Publisher: GBI Research More...

Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment Price Single User $3,500.00 Site License $7,000.00 Global Site License $10,500.00 Publication Date: 01-Apr-2011 Format: PDF Pages: 130 Publisher: GBI Research More...

Pharmaceutical Key Trends 2011 – Biosimilar Market Overview Price: $3,800.00 (€2,891.26) ($4,560.00 (€3,469.51) Including VAT at 20%) Publication Date: 23-Feb-2011 Please click here for more information or to purchase this report at our partner store Comparative analysis of biosimilar drivers and resistors, key players, market access, pricing, and future launches across multiple markets including: the US, Japan, France, Germany, Italy, Spain, the UK, Australia, Brazil, Russia, India and China.

Competitor Analysis: Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors Price Single User $2,187.00 Site License $3,374.00 Global License $6,561.00 Publication Date: Feb 2011 Format: PDF Pages: 265 Publisher: La Merie Sample Pages The Competitive Intelligence Report Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors as of February 2011 provides a competitor analysis in the development pipeline of ten major classes of therapeutic proteins and their biosimilar and biobetter/biosuperior versions in regulated and less regulated markets including non-protein projects in these pharmacological classes: Erythropoietin (EPO) & Erythropoiesis Stimulating Agents (ESA), G-CSF & GM-CSF, Thrombopoietin & Thrombopoiesis Stimulating Agents, Interferon, Insulin, Coagulation Factors, Human Growth Hormone (hGH), FSH etc, Thrombolytics & Fibrinolytics, Enzyme Replacement Therapies. More...

2011 U.S. Biological Product Manufacturing Industry Report Price ENTERPRISE LICENSE $699.00 Publication Date: 15-Jan-2011 Format: PDF Pages: 67 Publisher: Barnes Reports The U.S. Biological Product Manufacturing Industry report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2011 current and 2012 forecast estimates on the size of the industry (sales, establishments, employment) nationally and for all 50 U.S. States and over 900 metro areas. New to the report this year are: financial ratios, number of firms and payroll estimates. The report also includes industry definition, 5-year historical trends on industry sales, establishments and employment, a breakdown of establishments, sales and employment by employee size of establishment (9 categories), and estimates on up to 10 sub-industries, including vaccines, serums, plasmas, antitoxins, toxiods, blood fractions and culture media. Table of Contents

U.S. Biopharmaceutical Market - Trends, Forecast, Competition & Strategic Analysis (2009 - 2016) Price Single User $4,650.00 Multi User $5,650.00 Corporate Licence $7,150.00 Enterprise Site Licence $9,000.00 Publication Date: Dec-2010 Format: PDF Pages: 378 Publisher: MarketsandMarkets Table of Contents This research report analyzes the U.S. biopharmaceuticals market and its growth factors, with special emphasis on the top companies in the field and their product pipeline. While it looks at the overall market size and presents forecast till 2016, a key focus of the report is the increasing role of biopharmaceutical products. The growing interest in biotechnology development has led to the metamorphosis of the pharmaceutical industry, resulting in the subset industry of biopharmaceuticals. The big players in the pharma industry, including Pfizer, Merck, and Novartis, have been the first few to reap the benefits of investing in biotechnology through both organic as well as inorganic growth mechanisms. Market forecasts include the biopharmaceuticals that are currently in the market as well as those that are projected to enter the market by the end of the forecast period in 2016. Market challenges, drivers, and restraints have also been identified and assessed. Selected late stage pipeline analysis is also included. This report analyzes the biopharmaceutical industry’s products, features, companies, market size and potential, and patent portfolios. The impact of the Medicare and Medicaid policies and individual plan behaviors on the biopharmaceutical industry is also discussed.

G-CSF & GM-CSF Price Site License $907.00 Global License $1,361.00 Publication Date: Jan 2011 Format: PDF Pages: 40 Publisher: La Merie The present Competitive Intelligence Report about G-CSF & GM-CSF products in the pipeline and off-patent products provides a competitor evaluation in the field of G-CSF & GM-CSF branded products in regulated markets and products in non-regulated markets, biosimilars (biogenerics, follow-on biologics) and next generation, longer acting products or new uses of G-CSF as of January 2011. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. More...

Global Biosimilars (Follow-on biologics) Market: An Analysis Price: $800.00 (€608.69) ($960.00 (€730.42) Including VAT at 20%) Publication Date: 01-Nov-2010 Format: PDF Pages: 36 Publisher: Koncept Analytics Biosimilars or FOBs (Follow-on biologics) refer to generic versions of patented branded biological drugs, developed subsequent to the patent expiry of brand name products. The biosimilars market is segmented into peptides, recombinant glycosylated proteins, recombinant non-glycosylated proteins, and others. In 2009, biosimilar recombinant non glycosylated protein products formed the largest market segment since blockbuster biopharmaceutical drug such as interferon, human growth hormone-Somatropin, insulin and G-CSF; belong to this class and have wide range of applications. Overburdened due to rising healthcare costs, ageing population, expensive drugs and pharmaceutical expenditure, biosimilar market is getting boost from increasing user acceptance and emerging Indian and Chinese markets. The major challenge for the biosimilar market is risk involved with the high investment and possible failure of the drug during development stages. However, opportunities for biosimilar market is immense, as biologics are going to be off patent by 2015 and an anticipated approval pathway in U.S will open up potentially largest market. The growth potential of the biosimilars market is expected to be strong, with patents for a number of second-generation therapeutic proteins (Enbrel, Remicade, Herceptin, etc.) slated for expiry between 2013 and 2019. The global biosimilars market is highly fragmented with the presence of some leading players such as Biocon, Dr Reddy's Lab, Intas, LG LifeSciences, Ranbaxy, Reliance LifeSciences, Sandoz, Teva, and Wockhardt. The report titled “Global Biosimilars (Follow-on biologics) Market: An Analysis” covers the overview, market size and segmentation of the biosimilars market. The various drivers and the challenges faced by the market are also discussed in detail. The competitive aspect of the market is also highlighted and the key players are profiled with their strategies for this market. Table of Contents/List of Tables/List of Figures

Downstream Processing in Biopharmaceuticals - Increased Demand for Biologics Drives Improvement in Cost -effective Purification Technologies Price Single User $3,500.00 Site License $7,000.00 Global Site License $10,500.00 Publication Date: 1-Nov-2010 Format: PDF Pages: 91 Publisher: GBI Research Sample Pages GBI Research's report, “Down Stream Processing in Biopharmaceuticals - Increased Demand for Biologics Drives Improvement in Cost-effective Purification Technologies”, provides the key data and analyzes the major challenges and drivers for the downstream industry. The report also analyzes the strengths, weaknesses of and opportunities for the stakeholders in the downstream processing of biopharmaceuticals. The report also discusses the key market drivers and barriers for the growth of biomanufacturing in the pharmaceutical and biotech industry. The report is based on proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts to provide a comprehensive view of the Down Stream Processing in Biopharmaceuticals. More...

Competitor Analysis Biosimilar and Biobetter/Biosuperior Antibodies Price Single User $961.00 Site License $1,922.00 Global License $2,882.00 Publication Date: October-2010 Format: PDF Pages: 106 Publisher: La Merie The present Competitive Intelligence Report about Biosimilar and Biobetter/Biosuperior Antibodies provides a competitor evaluation in the field of recombinant monoclonal and polyclonal antibodies directed against CD20, Her2, VEGF, TNF, EGF-R, RSV and GPIIb/IIIa as of October 2010. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. More...

Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Price Single User $3,500.00 Site License $7,000.00 Global Site License $10,500.00 Publication Date: 01-Sep-2010 Format: PDF Pages: 156 Publisher: GBI Research More...

7th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production Price Hardcover $845.00 Digital Global License $1,690.00 Publication Date: 30-Apr-2010 Pages: 330 pages, 140 data graphs Publisher: BioPlan Associates, Inc. 7th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production. This comprehensive look at the state of worldwide biopharmaceutical manufacturing provides the only on-going assessment of manufacturing capacity and production in this $120 billion global industry. You will find current, quantitative information from 326 worldwide biopharmaceutical developers and contract manufacturers, and over 125 suppliers to the industry. Coverage includes: In-depth analysis and summary of the key survey findings, trends and implications for industry-wide biomanufacturing capacity and biotherapeutic production. Comparison of production by biotherapeutic developers and contract manufacturing organizations. Current and future potential industry bottlenecks . Trend analysis in this 7th in a series of annual biopharmaceutical manufacturing industry evaluations. Projected capacity bottlenecks, and how they might be resolved. This edition includes the joint industry expertise from BioPlan Associates, and many industry consultants and experts

6th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production Price Hardcover $845.00 Digital Global License $1,690.00 Publication Date: 01-Apr-2009 Pages: 224 Publisher: BioPlan Associates, Inc. This comprehensive look at the state of worldwide biopharmaceutical manufacturing provides the only on-going assessment of manufacturing capacity and production in this $90 billion global industry. You will find current, quantitative information from worldwide biopharmaceutical developers and contract manufacturers. ISBN: 978-1-934106-16-7 Table of Contents

Biopharmaceutical Products in the US and European Markets, WEB VERSION 7th Generation Price Single User Licence $795.00 Digital Global License $2,500.00 Publication Date: 01-Jul-2009 Pages: 1800 Publisher: BioPlan Associates, Inc. 7th Generation, fully on-line Reference databases concerning biopharmaceutical products. Table of Contents

Global Bio-Pharma CMO Market Report Price: $700.00 (€532.60) ($840.00 (€639.12) Including VAT at 20%) Publication Date: 01-May-2010 Format: PDF Pages: 32 Publisher: Koncept Analytics Large pharmaceutical companies increasingly turn to contract manufacturing organizations (CMOs) solely to achieve efficiencies in cost, capacity and time-to-market, or to obtain a specific expertise not available in-house. Today, these factors still play a role, but now the most dynamic driver behind the use of CMOs in the bio-pharmaceutical industry is the integration of innovative and state-of-the-art process and production technologies. The global bio-pharma CMO market has witnessed high growth over the last few years. The share of the CMO market of the total Bio-Pharma market has also increased over the period 2001-08. The growth in the bio-pharma CMO market has been fuelled by the outsourcing trend. Over the years outsourcing has become more of a strategic decision as companies look to lower their cost and capital requirements of setting up a plant. However, some factors like global economic crisis, intellectual property risk, increasing regulatory cost and lack of integrated CMOs are acting as a roadblock in the path of overall industry growth which the industry players need to tackle in order to grow in the long term. The bio-pharma CMO market can be segmented into Mammalian CMO market and Microbial CMO market. The largest share of the Bio-Pharma CMO market is held by the Mammalian CMO market. The current report analyzes the bio-pharma CMO market. The various drivers, opportunities and the challenges faced by the market are discussed in detail. The competitive aspect of the market is also highlighted and the key players are profiled with their strategies for this market. By combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the industry. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables and tests. Table of Contents/List of Tables/List of Figures

The Future of Biosimilars - Market Forecasts to 2015, Opportunity Analysis and Regulatory Pathways Price Single User $3,500.00 Site License $7,000.00 Global Site License $10,500.00 Publication Date: 31-Dec-2009 Format: PDF Pages: 97 Publisher: GBI Research More...

Small and Medium Biopharmaceutical Enterprises in North America and Europe - Biotechnology Clusters, Funding Characteristics and Regulatory Landscape Price Single User $3,500.00 Site License $7,000.00 Global Site License $10,500.00 Publication Date: 01-Feb-2010 Format: PDF Pages: 84 Publisher: GBI Research More...

Delivering New Biopharmaceutical Therapies: Challenges & Opportunities Price: $1,432.00 (€1,089.55) ($1,718.40 (€1,307.46) Including VAT at 20%) Published: 19/01/2009 Pages: 150 Format: PDF Publisher: Pharmavision This cutting edge & insightful report can be used to interpret & assess the potential of new biopharmaceuticals. It provides opinions & market projections to: • gain an in-depth understanding of the technological manufacturing & delivery issues which face companies developing the new generation of biopharmaceuticals; • evaluate the different options available for the efficient delivery of biopharmaceuticals now & in the future; • identify the key regulatory & production issues which face pharma & delivery specialists advancing the next generation biopharmaceuticals; • assess the therapeutic potential of new biopharmaceuticals targeting cancer, diabetes & immuno-inflammatory disorders; • identify which companies are developing biosimilars & discover which products & why they are most susceptible for copycat versions; • analyze how the biopharmaceutical market is evolving & the influence that delivery, regulation & biosimilars will have on the future development of biotherapeutics. Full Details Sample Pages

Biosimilars and Biobetters: Positioning for a New Market Please click here for more information or to purchase this report at our partner store Published: 01/07/2009 Pages: 275 Format: PDF Publisher: Select Biosciences The imminent expiries of several key biologics patents create opportunities for the development of biosimilars. This report analyzes the emerging market for first generation biosimilars and improved biosimilars (biobetters) and profiles 40 companies developing biosimilars worldwide. Scientific and sales data on almost 90 biologics on the market are used to derive market forecasts for biosimilars.

Biosimilars (2009 - 2014) Price Single User (+$4,650.00) Multi User (+$5,650.00) Corporate Licence (+$7,150.00) Enterprise Site Licence (+$9,000.00) Published: 9/24/2009 Pages: 189 Format: pdf Author: MarketsandMarkets Table of Contents Sample Pages The impending expiry of several patented blockbuster biopharmaceuticals and the increasing demand from patients, insurers, and government agencies to reduce drug costs have created numerous opportunities in the global biosimilars market. The global biosimilars market is expected to be worth US$19.4 billion by 2014, growing at a CAGR of 89.1% from 2009 to 2014. The biosimilars market is segmented into peptides, recombinant glycosylated proteins, recombinant non-glycosylated proteins, and others. The main factors driving the demand in the biosimilars market include increasing user acceptance, low costs and large application area, increasing governmental initiatives, and the emerging Indian and Chinese economies. The major challenges for the biosimilars market are the risks involved with the high investment and the possible failure of the drug during development stages. However, opportunities for biosimilars market is immense, as biologics worth US$25 billion are going to be off-patent by 2016; and an anticipated approval pathway in U.S. will open up potentially largest market. More...

MarketReports.com | Pharmaceuticals & Healthcare | Biotechnology |  Biopharmaceuticals